

Corresponding author(s):	Zheng Chen
Last updated by author(s):	Jul 14, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

_					
51	ta	ŤΙ	ist	IC	٠ς

For	all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact sam	pple size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	A statement of	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical Only common to	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.		
\boxtimes	A description	of all covariates tested		
\boxtimes	A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
\boxtimes		ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
\boxtimes		hesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted exact values whenever suitable.		
\boxtimes	For Bayesian a	analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
	'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
So	ftware and c	ode		
Policy information about <u>availability of computer code</u>				
Da	ata collection	ActiView software (circadian behavior), PiezoSleep Mouse Behavioral Tracking System (sleep recording), Oxymax-CLAMS (metabolic chamber assays), Mass Matrix, MAVEN (metabolite analysis), Seahorse XF24 Analyzer (mitochondrial bioenergetics).		

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.

Tophat2 v2.0.12, Cufflinks v2.2.1 (RNA-seq); MetaboAnalyst 3.0 package, GENE-E (metabolite analysis); additional data were analyzed

- Accession codes, unique identifiers, or web links for publicly available datasets

and plotted using Microsoft Excel, SigmaPlot and GraphPad Prism.

- A list of figures that have associated raw data
- A description of any restrictions on data availability

Data that support the findings of the current study are available from the corresponding author upon reasonable request. The GEO accession ID for the RNA-seq dataset is GSE134304 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134304]. The uncropped images of key western blots are presented in Supplementary Fig 7.

Field-specific reporting				
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of t	he document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces study design			
All studies must dis	close on these points even when the disclosure is negative.			
Sample size	Sample size was determined by established procedures for particular experiments; power analysis was performed when needed.			
Data exclusions	None			
Replication	All experiments were replicated at least three times with biologically independent samples			
Randomization	Aged mice acquired were randomized into treatment groups			
Blinding	Lab members collaborated on most experiments, and blinding was performed among lab members whenever possible (e.g., mouse techs provide the mice without disclosing treatment group).			
Reportin	g for specific materials, systems and methods			
We require information	on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,			
•	ed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
	perimental systems Methods			
n/a Involved in th				
Antibodies Eukaryotic	cell lines ChIP-seq			
Palaeontol				
	d other organisms			
	earch participants			
Clinical dat				
Antibodies				
Antibodies used	Antibodies used BMAL1 (epitope: aa 1-230, Cocalico Biologicals) and IgY were affinity purified using the same protein, 1:4000), RORα (epitope: ao 105-122, Cocalico Biologicals, 1:1000), RORγ (epitope: aa 212-230, Cocalico Biologicals; 1:1000), REV-ERBα (Millipore; 1:1000) and GAPDH (Santa Cruz SC25778; 1:5000). Anti-NDUFB8 mouse monoclonal antibody (1:2500 dilution) (ab110242, Abcam), Anti-UQCRC2 rabbit monoclonal antibody 1:2500 dilution (ab203832, Abcam), and Anti-MTCO1 (rabbit monoclonal antibody (1:5000 dilution) (ab203912, Abcam) were used respectively. Secondary anti-rabbit antibody (for CIII and CIV, stabilized peroxidase conjugate, Thermo Scientific) and armouse (for CI, stabilized peroxidase conjugate, Thermo Scientific) antibodies were used.			
Validation	All antibodies were validated following manufecturer's instruction.			
Eukaryotic cell lines				
Policy information about <u>cell lines</u>				
Cell line source(s	C2C12 from ATCC			
Authentication	The vendor provided evidence of authentication, and secondary validation via established differentiation protocols			

Cells were tested for mycoplasma using commercial kits and confirmed negative

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)

none

Animals and other organisms

 $Policy\ information\ about\ \underline{studies\ involving\ animals;}\ \underline{ARRIVE\ guidelines}\ recommended\ for\ reporting\ animal\ research$

Laboratory animals	Mice at different ages
Wild animals	n/a
Field-collected samples	n/a
Ethics oversight	All animal studies were approved by UTHealth Center for Laboratory Animal Medicine and Care (CLAMC) and were conducted in compliance with CLAMC designated guidelines.

Note that full information on the approval of the study protocol must also be provided in the manuscript.